| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00001432-200212000-00007 |
| P698 | PubMed publication ID | 12821836 |
| P50 | author | Shyam Sundar | Q58941021 |
| P2093 | author name string | Madhukar Rai | |
| P433 | issue | 6 | |
| P304 | page(s) | 593-598 | |
| P577 | publication date | 2002-12-01 | |
| P1433 | published in | Current Opinion in Infectious Diseases | Q15724406 |
| P1476 | title | Advances in the treatment of leishmaniasis | |
| P478 | volume | 15 |
| Q38088424 | (Post-) Genomic approaches to tackle drug resistance in Leishmania. |
| Q38395724 | Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions |
| Q38220355 | An overview of visceral leishmaniasis elimination program in India: a picture imperfect |
| Q46446564 | Antileishmanial and antibacterial activity of a new pyrazole derivative designated 4-[2-(1-(ethylamino)-2-methyl- propyl)phenyl]-3-(4-methyphenyl)-1-phenylpyrazole |
| Q44226161 | Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis |
| Q44461576 | Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone |
| Q28383050 | Coating doxorubicin-loaded nanocapsules with alginate enhances therapeutic efficacy against Leishmania in hamsters by inducing Th1-type immune responses |
| Q34141596 | Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters |
| Q39174889 | Development of doxorubicin loaded novel core shell structured nanocapsules for the intervention of visceral leishmaniasis |
| Q45836305 | Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis |
| Q37702257 | Drug delivery strategies for therapy of visceral leishmaniasis |
| Q39030698 | Drug regimens for visceral leishmaniasis in Mediterranean countries. |
| Q28483875 | Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis |
| Q27350034 | Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors |
| Q39017451 | Effect of Bixa orellana against Leishmania amazonensis |
| Q34024866 | Effectiveness and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis under Routine Program Conditions in Bihar, India |
| Q38376759 | Efficacy of a Binuclear Cyclopalladated Compound Therapy for Cutaneous Leishmaniasis in the Murine Model of Infection with Leishmania amazonensis and Its Inhibitory Effect on Topoisomerase 1B. |
| Q80032357 | Histopathological and immunohistochemical study of type 3 complement receptors (CD11b/CD18) in livers and spleens of asymptomatic and symptomatic dogs naturally infected with Leishmania (Leishmania) chagasi |
| Q34792941 | IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis |
| Q34240036 | Improving outcome of treatment of kala-azar by supplementation of amphotericin B with physiologic saline and potassium chloride |
| Q39649437 | In vitro activity of nicotinamide/antileishmanial drug combinations |
| Q35270608 | In vitro and in vivo studies of the utility of dimethyl and diethyl carbaporphyrin ketals in treatment of cutaneous leishmaniasis |
| Q38886248 | In vitro susceptibility to antimonials and amphotericin B of Leishmania infantum strains isolated from dogs in a region lacking drug selection pressure. |
| Q39200387 | In-silico analyses of sesquiterpene-related compounds on selected Leishmania enzyme-based targets. |
| Q26777203 | Kinetoplastid Membrane Protein-11 as a Vaccine Candidate and a Virulence Factor in Leishmania |
| Q37274842 | Leishmania major phosphoglycans influence the host early immune response by modulating dendritic cell functions |
| Q57000620 | Liposomal Amphotericin B and HIV-Associated Visceral Leishmaniasis : Concerns about Nephrotoxicity and Administration Schedule |
| Q36486228 | Mechanisms of drug action and drug resistance in Leishmania as basis for therapeutic target identification and design of antileishmanial modulators |
| Q35066668 | Noninvasive molecular diagnosis of human visceral leishmaniasis |
| Q35917392 | Progress in the treatment of a neglected infectious disease: visceral leishmaniasis |
| Q37251607 | Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis |
| Q38871733 | Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection |
| Q39367824 | Shp1 function in myeloid cells |
| Q36229304 | Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis |
| Q36331518 | Synthesis, SAR and biological studies of sugar amino acid-based almiramide analogues: N-methylation leads the way. |
| Q27671551 | The Leishmania nicotinamidase is essential for NAD+ production and parasite proliferation |
| Q37333942 | Therapeutic options for visceral leishmaniasis |
| Q39954346 | Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. |
| Q34510966 | Treatment options for visceral leishmaniasis |
| Q42080432 | Uptake of biodegradable gel-assisted LBL nanomatrix by Leishmania donovani-infected macrophages |
| Q39226324 | Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani |
| Q36112187 | rK39 antigen for the diagnosis of visceral leishmaniasis by using human saliva |
Search more.